Genelux Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GNLX Nasdaq 2836 www.genelux.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genelux Corporation

Genelux Corporation Announces New Chief Financial Officer - Feb 3rd, 2025 11:45 am
We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Jan 24th, 2025 1:51 pm
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - Dec 13th, 2024 12:01 pm
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts - Nov 15th, 2024 2:50 pm
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates - Nov 14th, 2024 9:05 pm
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference - Nov 6th, 2024 9:01 pm
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well - Oct 31st, 2024 11:37 am
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp - Oct 25th, 2024 5:01 pm
Genelux doses first subject in Phase II trial of NSCLC treatment - Oct 23rd, 2024 3:27 pm
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer - Oct 22nd, 2024 8:01 pm
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit - Oct 9th, 2024 8:15 pm
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference - Sep 3rd, 2024 8:01 pm
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - Aug 17th, 2024 1:43 pm
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates - Aug 14th, 2024 8:05 pm
Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds - Aug 12th, 2024 9:16 pm
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024 - Jul 30th, 2024 11:00 am
Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop - May 24th, 2024 12:58 pm
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants - May 24th, 2024 12:00 pm
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants - May 23rd, 2024 8:01 pm
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates - May 9th, 2024 8:25 pm